Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS CSL to Bring 1st Hemophilia B Gene Therapy to Japan Too; Eyes Riveted on Price Tag
December 9, 2022
-
BUSINESS Merck CEO Wants to See Japan’s Shift to Pro-Innovation Structure in 2024 Reform
December 9, 2022
-
REGULATORY First Generics for 5 APIs Join NHI Price List, Main Targets Are Nexium/Lexapro
December 9, 2022
-
REGULATORY Industry Prods Special Inflation Measure in Off Year, Payers Don’t See Much Need: Chuikyo Hearing
December 8, 2022
-
ORGANIZATION FPMAJ Poll Finds Worsening Supply Woes with 28% of Drugs Restricted or Suspended
December 7, 2022
-
ACADEMIA Lewy Body Dementia Specialist Sees Aricept Approval Modification as Positive Move
December 6, 2022
-
REGULATORY NHI-Market Price Gap Narrowed, but Chuikyo Payer Reps Say Normal Revision Possible
December 5, 2022
-
REGULATORY Average NHI-Market Price Gap for 2023 Off-Year Revision at 7.0%: MHLW
December 2, 2022
-
BUSINESS AstraZeneca Japan Set to Buttress Respiratory Business with Tezspire Debut
December 2, 2022
-
BUSINESS Ultragenyx to Ramp Up Ultra-Orphan Drug Development, Bolster Hiring in Japan
December 1, 2022
-
BUSINESS Eisai Says 2 Trial Deaths Not Attributed to Lecanemab, No Change in Submission Plan
December 1, 2022
-
REGULATORY MOF Panel Presses for Full Annual Price Cuts, Rethink of COVID-Related Government Purchase
November 30, 2022
-
BUSINESS No Direct Causal Link between Lecanemab and Death in Clinical Trial: Eisai
November 30, 2022
-
REGULATORY Orlistat in Line for Approval as Japan’s 1st Nonprescription Obesity Drug after 4-Year Review
November 29, 2022
-
COMMENTARY Japan Should Hone Emergency Approval Scheme Based on Xocova Example
November 28, 2022
-
BUSINESS Shionogi Chief Defends Xocova Data, Eager to Prove Benefits in Clinical Settings
November 25, 2022
-
REGULATORY Japan Grants 1st Emergency Approval to Shionogi COVID Pill Xocova
November 24, 2022
-
COMMENTARY Pharma Industry Stays Pat on “No” to Off-Year Plan, Why Not Going for Trade-Off?
November 22, 2022
-
ACADEMIA Academic Societies Warn against Hoarding Meropenem as Supply Crunch Intensifies
November 21, 2022
-
BUSINESS Big 3 Generic Firms Struggle in H1; Nichi-Iko Logs Excess Debt as Profits Tank for Rivals
November 18, 2022
ページ
President Joe Biden enacted the Inflation Reduction Act (IRA) on August 16, 2022, significantly affecting Medicare prescription drug coverage and introducing targeted changes to Medicaid, the Children’s Health Insurance Program, and private health insurance. In January 2023, the Centers for…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…